News

Almost two years of treatment with Kaftrio (elexacaftor, tezacaftor, and ivacaftor) did not affect liver stiffness — an indicator of liver fibrosis — in adults with cystic fibrosis (CF), according to a recent study in the U.K. However, patients with elevated markers of liver stiffness before starting on…

The lungs of people with cystic fibrosis (CF) harbor stem cells with a distinctive proinflammatory genetic signature, a new study shows. Data indicate that the proinflammatory genetic profile of these stem cells is not affected by treatment with CFTR modulators, a class of medications that can boost the…

CFTR modulator therapy was associated with increases in fecal levels of the pancreatic elastase-1 enzyme (FE-1), reflecting improved pancreatic function, among young cystic fibrosis (CF) patients in a recent study. A small subset of patients achieved FE-1 levels high enough that they were no longer considered to have…

The Cystic Fibrosis (CF) Foundation is giving up to $9 million in additional support to advance clinical testing of ARCT-032, a messenger RNA therapy with the potential to benefit anyone with CF, regardless of their disease-causing mutation. Arcturus Therapeutics, the inhalation therapy’s developer, is using the funding…

People with cystic fibrosis (CF) in the U.S. tend to live more than a decade longer now than patients did about 20 years ago, according to a study that found deaths from CF have about halved from 1999 to 2020. “These changes were relatively slow during an earlier period…

Regular assessments of food security — a measure of whether nutritionally adequate foods are available — are linked with a lower risk of children with cystic fibrosis (CF) being underweight, a U.S. study reports. Such assessments are also associated with better body mass index (BMI; a measure of body…

ReCode Therapeutics has raised $50 million in extended series B financing, which the company plans to use to help develop RCT2100, its experimental treatment for cystic fibrosis (CF). “We are delighted with the continued high level of interest in our novel approach to the targeted delivery of genetic…

Inogen has acquired Physio-Assist, including Simeox, a technology for airway clearance and mucus management in people with cystic fibrosis (CF). The company will continue marketing Simeox in Europe, Asia, and the Middle East, while pursuing regulatory clearance in the U.S. This acquisition will expand Inogen’s portfolio of…

The public is invited to help select this year’s two AbbVie Cystic Fibrosis Scholarship “Thriving Students,” who will be awarded an additional $22,000 in support of their higher education. As it has done for decades, AbbVie gave scholarships worth $3,000 to 40 undergraduate and graduate students living…

Researchers from Vertex Pharmaceuticals have been awarded the 2024 Breakthrough Prize in Life Sciences for their work developing CFTR modulator therapies for people with cystic fibrosis (CF). Breakthrough Awards, known as the “Oscars of Science,” are granted to scientists who have made important discoveries in life sciences, fundamental…